Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study

Abstract

Anti-TNF was frequently used among patients with EIM. In more than 40%, anti-TNF treatments are started to treat EIM rather than IBD. Given the good response rates, anti-TNF seems to be a valuable option in the treatment of EIM, whereas appearance of EIM under anti-TNF does not seem to be a source of considerable concern.

Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease

“…adult population (71.8%) (35). New onset of EIM under anti-TNF treatment also has been encountered in our study.…”

Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort

“…Paradoxical manifestation was defined as the appearance of new‐onset manifestations under vedolizumab therapy, confirmed by a dermatologist and/or a rheumatologist as a paradoxical manifestation and including cutaneous paradoxical manifestation (psoriasiforma and eczematiform), rheumatological paradoxical manifestation and lupus‐like manifestation . Efficacy on EIM was calculated retrospectively using a simple 3‐step scale used in previous studies . Briefly, patients were categorized as having the following: (1) no response, meaning no improvement or worsening of symptoms; (2) partial response, meaning improvement of symptoms or reduction in the steroid dose without worsening of symptoms; or (3) complete remission, meaning absence or almost absence of all clinical symptoms without increasing the steroid dose.…”

Extraintestinal manifestations in inflammatory bowel disease – epidemiology, genetics, and pathogenesis

“…Recent studies have suggested efficacy of anti-TNF in the management of various EIM. 97,98 Anti-TNF appear to be particularly efficacious in the treatment of cutaneous EIM and arthritis, although most data evolve from non-controlled open-label trials or non-interventional (retrospective) studies.…”